Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600, Singapore.
Department of Biomedical Sciences, College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Kowloon, Hong Kong.
Cells. 2020 Sep 29;9(10):2191. doi: 10.3390/cells9102191.
Despite the recent advances in drug development, the majority of novel therapeutics have not been successfully translated into clinical applications. One of the major factors hindering their clinical translation is the lack of a safe, non-immunogenic delivery system with high target specificity upon systemic administration. In this respect, extracellular vesicles (EVs), as natural carriers of bioactive cargo, have emerged as a promising solution and can be further modified to improve their therapeutic efficacy. In this review, we provide an overview of the biogenesis pathways, biochemical features, and isolation methods of EVs with an emphasis on their many intrinsic properties that make them desirable as drug carriers. We then describe in detail the current advances in EV therapeutics, focusing on how EVs can be engineered to achieve improved target specificity, better circulation kinetics, and efficient encapsulation of therapeutic payloads. We also identify the challenges and obstacles ahead for clinical translation and provide an outlook on the future perspective of EV-based therapeutics.
尽管药物研发最近取得了进展,但大多数新型疗法尚未成功转化为临床应用。阻碍它们临床转化的一个主要因素是缺乏一种安全、非免疫原性的给药系统,在全身给药时具有高靶向特异性。在这方面,细胞外囊泡 (EV) 作为生物活性货物的天然载体,已经成为一种很有前途的解决方案,并且可以进一步修饰以提高其治疗效果。在这篇综述中,我们提供了 EV 的生物发生途径、生化特征和分离方法的概述,重点介绍了它们作为药物载体的许多内在特性。然后,我们详细描述了 EV 治疗的最新进展,重点介绍了如何对 EV 进行工程改造以实现更好的靶向特异性、更好的循环动力学和更有效地封装治疗有效载荷。我们还确定了临床转化前面临的挑战和障碍,并对基于 EV 的治疗的未来前景进行了展望。